Clinical Trial Update: A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab [Phase 2]

View source ↗

Summary

Multicenter, two-arm Phase 2 trial evaluating perioperative therapy for HER2-positive resectable esophagogastric junctional adenocarcinoma, comparing Nabulimab …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagogastric Junction

Drugs mentioned

• 5-Fluorouracil (5-FU)
• DOCETAXEL (DOCETAXEL)
• Leucovorin (folinic acid)
• Nabulimab
• OXALIPLATIN (Oxaliplatin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: xiaohua li | Conditions: Adenocarcinoma of the Esophagogastric Junction, Perioperative Period | Phase 2 | Status: ACTIVE_NOT_RECRUITING